[Form 3] CG Oncology, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) filed a Form 3 reporting that its Interim Principal Financial and Accounting Officer, James M. DeTore, currently holds no beneficial ownership of the company’s securities. The filing identifies him as an officer of CG Oncology and confirms that no non-derivative or derivative securities are reported as beneficially owned. The Form 3 is filed by a single reporting person and serves as an initial ownership statement required under securities regulations.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

DETORE JAMES M.

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/17/2025

3. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Interim Principal Financial and Accounting Officer

No securities are beneficially owned.

	/s/ Joshua Patterson, Attorney-in-Fact for James M. DeTore	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the CG Oncology (CGON) Form 3 filing disclose?

The Form 3 discloses that Interim Principal Financial and Accounting Officer James M. DeTore currently has no beneficial ownership of CG Oncology, Inc. securities.

Who is the reporting person in this CGON Form 3?

The reporting person is James M. DeTore, who is identified as the company’s Interim Principal Financial and Accounting Officer.

Does the officer own any CG Oncology (CGON) shares or options?

No securities are reported as beneficially owned. The remarks section explicitly states: “No securities are beneficially owned.”

Is this CG Oncology Form 3 filed by one person or a group?

The document indicates that the Form is filed by one reporting person, not by a joint group.

What is the date of the event requiring this Form 3 for CGON?

The date of the event requiring this initial statement of beneficial ownership is listed as 11/17/2025.

What role does James M. DeTore hold at CG Oncology (CGON)?

The remarks identify James M. DeTore as the company’s Interim Principal Financial and Accounting Officer.